Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bhaswati Mukherjee

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Diabetes Technology & Therapeutics|December 14, 2019
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical TrialJames Thrasher, Sarit Polsky, Lionel Hovsepian, et al.
Diabetes, Obesity & Metabolism|October 20, 2022
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trialTadej Battelino, Thomas Danne, Steve V Edelman, et al.
Diabetes Technology & Therapeutics|December 6, 2019
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)Satish K Garg, Karin Wernicke-Panten, Marek Wardecki, et al.
Plos One|June 7, 2018
Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune modelErnesto Luna, Pankaj Agrawal, Riyaz Mehta, et al.
Diabetes Technology & Therapeutics|February 19, 2020
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 TrialSatish K Garg, Karin Wernicke-Panten, Marek Wardecki, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 1, 2022
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix InsulinS R Aravind, Kiran P Singh, Liliia Mogylnytska, et al.
Diabetes, Obesity & Metabolism|October 26, 2023
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.
Journal of Diabetes Science and Technology|February 29, 2024
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X TrialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 14, 2022
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)S R Aravind, Kiran P Singh, Grace Aquitania, et al.
Eclinicalmedicine|March 28, 2024
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trialCuthbert Simpkins, Michael Moncure, Heather Klepacz, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Diabetes Technology & Therapeutics|December 14, 2019
Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical TrialJames Thrasher, Sarit Polsky, Lionel Hovsepian, et al.
Diabetes, Obesity & Metabolism|October 20, 2022
Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trialTadej Battelino, Thomas Danne, Steve V Edelman, et al.
Diabetes Technology & Therapeutics|December 6, 2019
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)Satish K Garg, Karin Wernicke-Panten, Marek Wardecki, et al.
Plos One|June 7, 2018
Evaluation of the innate immunostimulatory potential of originator and non-originator copies of insulin glargine in an in vitro human immune modelErnesto Luna, Pankaj Agrawal, Riyaz Mehta, et al.
Diabetes Technology & Therapeutics|February 19, 2020
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 TrialSatish K Garg, Karin Wernicke-Panten, Marek Wardecki, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 1, 2022
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix InsulinS R Aravind, Kiran P Singh, Liliia Mogylnytska, et al.
Diabetes, Obesity & Metabolism|October 26, 2023
Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.
Journal of Diabetes Science and Technology|February 29, 2024
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X TrialViral N Shah, Amer Al-Karadsheh, Cathy Barnes, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 14, 2022
Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)S R Aravind, Kiran P Singh, Grace Aquitania, et al.
Eclinicalmedicine|March 28, 2024
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trialCuthbert Simpkins, Michael Moncure, Heather Klepacz, et al.
Pageof 2